Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD

CHENGDU, China and ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating treatment with KH658 for patients with wet Age-related Macular Degeneration (wet AMD). This multi-center, open-label, dose-escalation clinical trial in the U.S. will assess the safety, tolerability and efficacy of KH658 as a single suprachoroidal space administration of gene therapy for patients with previously treated wet AMD.

KH658 is a recombinant adeno-associated virus vector that encodes a human VEGF receptor fusion protein. In preclinical studies of wet AMD disease models, suprachoroidal space administration of KH658 resulted in retention of the transgene product in the retina for prolonged periods and prevented the disease progression. These findings may indicate the potential of KH658 to offer a single administration treatment for wet AMD patients.

“Dosing our first patient in the VAN-2401 Phase 1 trial is an important milestone in the advancement of KH658 by exploring the potential of single suprachoroidal space administration of gene therapy as treatment for wet AMD. KH658 is designed to deliver anti-VEGF continuously to the retina, with the potential to provide sustained levels that can control the disease,” said Avner Ingerman, M.D., Chief Medical Officer of Vanotech.

“I am excited to participate as a principal investigator in this important study. Dosing the first patient is an important milestone in the development of the single-administration gene therapy approach, which may hold promise to our patients in need of frequent treatment for their retinal diseases,” said Mark Barakat, M.D., a principal investigator in the VAN-2401 Phase 1 trial, Director of Research at Retina Macula Institute of Arizona in Scottsdale Arizona.

About the VAN-2401 Phase 1 Clinical Trial
VAN-2401 is a Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration. The study is expected to include approximately nine previously treated wet AMD subjects that are responsive to anti-vascular endothelial growth factor (anti-VEGF) therapy. For more information, please visit https://www.clinicaltrials.gov/study/NCT06825858

About Wet AMD
Wet AMD is the rarer form of AMD, characterized by loss of vision due to abnormal blood vessel formation in and under the retina. These blood vessels tend to leak, and the fluid interferes with the normal retinal structure and function, leading to vision loss. Wet AMD is a leading cause of irreversible vision loss or blindness in the United States and Europe, especially if left untreated. It is estimated that ~1.5 million people living with wet AMD in the United States.

Anti-VEGF therapies have become the standard of care for wet AMD. Anti-VEGF treatments reduce leakage and fluid accumulation, thereby restoring normal retinal architecture and function, in many patients. Anti-VEGF agents often require frequent, repeat injections to maintain efficacy and control the disease.

About Chengdu Origen and Vanotech
Chengdu Origen is a clinical-stage gene therapy company focused on developing gene therapy for unmet medical needs and providing meaningful clinical benefits for patients suffering from genetic and chronic diseases and has comprehensive viral vector manufacturing capabilities and infrastructure.

Vanotech is operating as the sponsor-representative, and is responsible for the clinical development program of KH658 in the United States. Vanotech is also currently conducting VAN-2201, a Phase 1, multi-center, open-label, dose-escalation study in subjects with wet AMD to evaluate safety, tolerability and efficacy of a single administration of KH631. For more information, please visit https://www.clinicaltrials.gov/study/NCT05657301.

Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Chengdu Origen’s and Vanotech’s research and development plans in connection with its clinical development program and the gene therapy treatments. Such forward-looking statements include inherent risks and uncertainties, including factors that could cause actual results to differ materially from those projected by such forward-looking statements. All of Chengdu Origen/Vanotech development timelines could be subject to adjustment depending on recruitment rate, regulatory agency review and other factors that could delay the initiation and completion of clinical trials. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of pandemics and other health emergencies, including their impact on the global supply chain; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical studies; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products;

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release. Chengdu Origen and Vanotech undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise.


Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

For more information please contact avner.ingerman@cnkh.com

THỦ THUẬT HAY

Kinh nghiệm cần biết cho những người mua máy ảnh DSLR

Bài viết này sẽ hướng dẫn cho các bạn một cách chi tiết cách test và chọn mua những chiếc máy ảnh DSLR đã qua sử dụng.

Cách điều khiển Netflix, YouTube, VLC trên PC bằng điện thoại

Bạn không sở hữu SmartTV hay các thiết bị phát kỹ thuật số có thể truyền lên TV không có nghĩa là không thể dùng điện thoại để điều khiển những gì bạn đang xem trên Netflix.

Scan tài liệu trên điện thoại Android với Camscanner

Khi bạn cần gửi một bản scan chuyên nghiệp thì ngoài việc ra cửa hàng scan, bạn có thể sử dụng các ứng dụng có sẵn trên điện thoại. Trong bài viết này, tôi sẽ giới thiệu tới bạn đọc một trong những ứng dụng tốt nhất -

Bỏ túi ngay cách nạp tiền vào App Store cực đơn giản và nhanh chóng

Bạn đang muốn tải một ứng dụng hoặc một game tính phí nhưng lại chưa có tiền trong tài khoản của App Store. Bạn muốn nạp tiền vào tài khoản App Store nhưng lại không biết cách.

6 tiện ích mở rộng Gmail miễn phí trên Chrome mà bạn cần biết

Tất cả các tiện ích mở rộng sẽ mang lại hiệu quả sử dụng cao hơn cho bạn từ tăng tốc quá trình đính kèm đến viết ghi chú, nhắc nhở... Bạn có thể cài đặt Chrome extensions trên trình duyệt Opera hoặc các trình duyệt nền

ĐÁNH GIÁ NHANH

Những trải nghiệm tuyệt vời trên Galaxy A52s 5G: Cấu hình tốt, camera chống rung quang học OIS tuyệt vời

Galaxy A52s, sản phẩm khiến mình cảm thấy hài lòng nhất trong năm 2021 này, một thiết bị hỗ trợ nhiều tính năng chuyên nghiệp như quay video chống rung OIS, ngoài ra còn có cấu hình mạnh mẽ, thoải mái xử lý công việc

Đánh giá nhanh chiếc điện thoại Galaxy C9 Pro tại Việt Nam

Galaxy C9 Pro có hiệu năng tương đương với Galaxy S7 / S7 edge trong hầu hết các tác vụ phổ thông và công việc hằng ngày. Thiết kế đẹp, rất đẹp, màn hình to, rất to nhưng máy mỏng, rất mỏng...

Trên tay OPPO F5 Youth: Fullview 6-inch Full-HD+, vi xử lý Helio P23, pin 3.200 mAh

OPPO F5 Youth vẫn trung thành với kiểu thiết kế giả kim loại giống như mẫu F5, với các góc cạnh được bo tròn mềm mại kết hợp cùng màn hình tỉ lệ 18:9 giúp cho cảm giác cầm nắm sử dụng máy rất thoải mái ngay cả với một